Close Menu

coronary artery disease

NEW YORK (GenomeWeb News) – CardioDx today said that it has joined a research effort launched by Duke University and the National Heart Lung and Blood Institute aimed at determining alternative diagnostic strategies for assessment of patients with symptoms that suggest coronary artery disease.

CardioDx this week completed a $58 million private equity financing round that it will use to support sales of its Corus CAD test and the development of additional diagnostics.

NEW YORK (GenomeWeb News) – Cardiovascular genomics diagnostics company CardioDx today announced the completion of a $58 million equity financing round.

NEW YORK (GenomeWeb News) – CardioDx today announced that national Medicare contractor Palmetto GBA will cover the company's Corus CAD gene expression test for coronary artery disease.

AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.

Researchers at the University of California, Davis have reeled in a $1 million grant from the W.M. Keck Foundation to study genetic variants that may be involved in some cases of coronary artery disease.

CardioDx will use the funding to complete additional studies that demonstrate the clinical utility of Corus CAD, continue to educate primary care physicians and cardiologists as to how the test can be used in the care of their patients, and reach out to payors to help them understand the circumstances under which they should pay for the test.

The cardiovascular genomics testing firm will use the funding to expand reimbursement coverage in the US for its gene expression Corad CAD test.

Quest, which plans to acquire Celera by the end of the month, could provide the financial backing to conduct prospective studies for the KIF6 test, or it could decide to scrap the KIF6 program altogether.

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.